ADDERALL 20 Drug Patent Profile

When do Adderall 20 patents expire, and what generic alternatives are available?

Adderall 20 is a drug marketed by Teva Womens and is included in one NDA.

The generic ingredient in ADDERALL 20 is amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate. There are fifty-five drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate profile page.

Summary for ADDERALL 20

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	40
Patent Applications:	1
DailyMed Link:	ADDERALL 20 at DailyMed

Recent Clinical Trials for ADDERALL 20

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Boston Children's Hospital	Phase 1
Eva Szigethy	Phase 4
The Beckwith Institute	Phase 4

See all ADDERALL 20 clinical trials

US Patents and Regulatory Information for ADDERALL 20

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Womens	ADDERALL 20	amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate	TABLET;ORAL	011522-008	Feb 13, 1996		DISCN	Yes	No

Expired US Patents for ADDERALL 20

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Womens	ADDERALL 20	amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate	TABLET;ORAL	011522-008	Feb 13, 1996

International Patents for ADDERALL 20

See the table below for patents covering ADDERALL 20 around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2003504406
Australia	6089200
World Intellectual Property Organization (WIPO)	0105407
European Patent Office	1202739
Mexico	PA02000290	FORMA DE DOSIFICACION ORAL DE LIBERACION INMEDIATA RAPIDA. (RAPID IMMEDIATE RELEASE ORAL DOSAGE FORM.)

ADDERALL 20 Market Analysis and Financial Projection Experimental

Adderall 20: Market Dynamics and Financial Trajectory

Introduction to Adderall

Adderall, a trade name for the drug amphetamine, is an FDA-approved prescription medication primarily used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy. It is available in both immediate-release and extended-release formulations, making it a versatile treatment option.

Market Size and Growth

The global Adderall drug market has been experiencing significant growth, driven largely by the increasing prevalence of ADHD. As of 2023, the market size was approximately USD 20.90 billion and is projected to grow at a Compound Annual Growth Rate (CAGR) of 4% between 2024 and 2032, reaching a value of about USD 29.75 billion by 2032[1][3].

Key Drivers of Market Growth

Increasing Prevalence of ADHD

The rising prevalence of ADHD is a primary driver of the Adderall market. ADHD diagnoses have been increasing steadily over the past decade, contributing to higher demand for stimulant medications like Adderall[2][3].

Demographic Factors

The senior population, which is more predisposed to neurological illnesses such as ADHD, is another significant factor driving market expansion. Additionally, the increasing awareness and diagnosis of ADHD among adults, particularly those in their 20s and 30s, have led to a surge in prescriptions for ADHD medications during the COVID-19 pandemic[1][4].

Healthcare Infrastructure

North America, with its advanced healthcare infrastructure, dominates the Adderall market. Europe and the Asia Pacific region also play significant roles, with the latter expected to grow at the highest CAGR during the forecast period due to increasing awareness about ADHD and rising healthcare expenditure[1][3].

Market Segmentation

By Disease Treatment

• Attention Deficit Hyperactivity Disorder (ADHD): The primary indication for Adderall, accounting for the majority of prescriptions.
• Narcolepsy: Another significant use for Adderall, though less common than ADHD.
• Others: Other off-label uses, though these are less prevalent[3].

By Distribution Channel

• Hospital-based Pharmacies: A key distribution channel, especially for patients requiring immediate medical attention.
• Retail Pharmacies: The most common distribution channel for Adderall prescriptions.
• Others: Including online pharmacies and specialty stores[3].

By Region

• North America: The largest market for Adderall, driven by high ADHD prevalence and advanced healthcare infrastructure.
• Europe: A significant market with key players and increasing investment in research and development.
• Asia Pacific: Expected to grow at the highest CAGR due to increasing awareness and healthcare expenditure.
• Latin America and Middle East & Africa: Also growing, though at a slower pace compared to other regions[1][3].

Supply Chain and Shortage Issues

Current Shortage

Adderall has been experiencing periodic shortages since 2019, with the most recent shortage affecting the supply of immediate-release tablets. This shortage is attributed to increased demand, particularly with children returning to classrooms post-pandemic, and manufacturing supply chain issues[2].

Impact on Patients

Patients are facing challenges in obtaining their prescribed doses, leading to the need for alternative formulations or pharmacies. RxSS and other support services are helping patients navigate these shortages by providing information on available alternatives and facilitating prescription changes[2].

Financial Implications

Revenue Projections

The projected growth of the Adderall market to USD 29.75 billion by 2032 indicates a robust financial trajectory. This growth is supported by the increasing demand for ADHD treatments and the expanding patient base[1][3].

Competitive Landscape

The market is highly competitive, with several key players focusing on developing new drugs and therapies. This competition drives innovation and ensures a steady supply of medications, although it also poses challenges in terms of market share and pricing strategies[3].

Regulatory Environment

DEA Quotas

The Drug Enforcement Administration (DEA) sets quotas for the production of controlled substances like Adderall. However, these quotas have been criticized for not keeping pace with the increasing demand, leading to shortages. There are ongoing efforts to address these issues and improve the quota system's transparency[4].

Consumer and Prescriber Trends

Increased Prescriptions During the Pandemic

The COVID-19 pandemic saw a significant increase in ADHD medication prescriptions, particularly among women and adults in their 20s and 30s. This trend highlights the growing need for ADHD treatments and the potential for overprescribing, which requires further research to differentiate between unmet needs and overprescription[4].

Alternative Treatments

Patients may be prescribed alternative medications such as Vyvanse®, Concerta®, or Focalin® if Adderall is not available or if side effects are undesirable. These alternatives are part of the broader ADHD drug class and can help manage the current shortage[2].

Regional Market Dynamics

North America

North America remains the largest market for Adderall, driven by high ADHD prevalence and advanced healthcare infrastructure. The region's strong pharmaceutical industry and high healthcare expenditure support the market's growth[1][3].

Europe

Europe is a significant market with key players and increasing investment in research and development. The presence of advanced healthcare systems and a high prevalence of ADHD contribute to the market's growth in this region[3].

Asia Pacific

The Asia Pacific region is expected to grow at the highest CAGR due to increasing awareness about ADHD, rising healthcare expenditure, and improving healthcare infrastructure. This region presents significant opportunities for market expansion[3].

Challenges and Opportunities

Supply Chain Disruptions

The COVID-19 pandemic highlighted vulnerabilities in the supply chain for pharmaceuticals, including Adderall. Addressing these disruptions is crucial for maintaining a stable supply of the medication[3].

Regulatory Changes

Efforts to improve the DEA quota system and address supply chain issues present opportunities for better market management and reduced shortages. These changes can help align production with demand more effectively[4].

Key Takeaways

• The global Adderall market is projected to grow significantly, driven by the increasing prevalence of ADHD.
• North America dominates the market, followed by Europe and the Asia Pacific region.
• Supply chain disruptions and DEA quotas are key challenges that need to be addressed.
• Alternative treatments and support services are crucial during periods of shortage.
• The market is highly competitive, with several key players focusing on innovation and market expansion.

FAQs

What is the primary driver of the Adderall market growth?

The primary driver of the Adderall market growth is the increasing prevalence of ADHD, which has been rising steadily over the past decade[1][3].

How has the COVID-19 pandemic affected Adderall prescriptions?

The COVID-19 pandemic led to a significant increase in ADHD medication prescriptions, particularly among women and adults in their 20s and 30s, due to increased awareness and reduced barriers to access[4].

What are the common alternatives to Adderall during shortages?

Common alternatives include switching to extended-release formulations, changing to higher or lower dose tablets, or using other ADHD medications like Vyvanse®, Concerta®, or Focalin®[2].

Why are there periodic shortages of Adderall?

Periodic shortages of Adderall are due to increased demand, particularly with children returning to classrooms post-pandemic, and manufacturing supply chain issues. The DEA quotas not keeping pace with demand also contribute to these shortages[2][4].

Which region is expected to grow at the highest CAGR for the Adderall market?

The Asia Pacific region is expected to grow at the highest CAGR during the forecast period due to increasing awareness about ADHD and rising healthcare expenditure[3].

Sources

1. Expert Market Research: Adderall Drug Market Size, Share | Industry Statistics 2032
2. RxSS: The Adderall Shortage Is Real – Here's How RxSS Helps Members
3. Research and Markets: Adderall Drug Market Report and Forecast 2023-2031
4. Additude Magazine: Adderall Shortage Update: Spike in ADHD Medication Prescriptions